{"id":394181,"date":"2020-12-07T08:03:18","date_gmt":"2020-12-07T13:03:18","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=394181"},"modified":"2020-12-07T08:03:18","modified_gmt":"2020-12-07T13:03:18","slug":"oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\/","title":{"rendered":"Oncorus Appoints Steve Harbin as Chief Operating Officer and Chief of Staff"},"content":{"rendered":"

\n— Former Moderna executive and industry veteran brings diverse operational expertise as Oncorus\u00a0plans buildout of its manufacturing capabilities to support its viral immunotherapy pipeline —
\n<\/h2>\n
\n

CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) — Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation viral immunotherapies to transform outcomes for cancer patients, today announced the appointment of Steve Harbin as Chief Operating Officer and Chief of Staff.<\/p>\n

\u201cI am thrilled to welcome Steve to the Oncorus team. He is uniquely qualified to help steer the strategic growth of our company at this pivotal timepoint,\u201d said Theodore (Ted) Ashburn, M.D. Ph.D., President and CEO of Oncorus. \u201cWe continue to advance the Phase 1 study of our lead viral immunotherapy candidate, ONCR-177, and progress our earlier stage viral immunotherapy candidates toward candidate nomination, including our innovative synthetic virus candidates. We believe that our infrastructure, organization and internal processes are poised for significant expansion in the coming months. Having Steve architect this evolution is an obvious choice.\u201d<\/p>\n

Mr. Harbin commented, \u201cI am excited to join the Oncorus team at this exciting time in the company\u2019s journey. It takes good science, good people and good business to develop and grow a leading biotech, and I have found them all here at Oncorus. The promise of Oncorus\u2019 two novel viral immunotherapy platforms is now transitioning to a key operational scale-up phase as the company\u2019s pipeline advances. I believe I can make a significant impact and execute the ambitious growth strategy Ted and the Oncorus Board have articulated, including the buildout of the company\u2019s manufacturing capabilities.\u201d<\/p>\n

Mr. Harbin brings more than 30 years of diverse operational experience in biotech, pharmaceuticals and in-vitro diagnostics. He has served in a variety of senior business and operational leadership roles, including 15 years at the executive committee level, for both publicly and privately held companies based in Europe and the U.S. Most recently, Mr. Harbin served as a consultant to several early stage biotech companies in the Cambridge community, providing strategic counsel related to operational scale-up challenges.<\/p>\n

Prior to that, Mr. Harbin served in several executive committee roles at Moderna, Inc. for six years as a Senior Vice President, joining the company when it was still at an early phase. Throughout his tenure at Moderna, Mr. Harbin was a key driver of the company\u2019s successful growth strategy, overseeing clinical and non-clinical manufacturing operations, supply chain, facilities and human resources. Mr. Harbin retired from Moderna in 2019, shortly after the company\u2019s initial public offering.<\/p>\n

Before joining Moderna, Mr. Harbin was based in France and held the position of Senior Vice President, Global Operations at bioM\u00e9rieux SA, where he managed over 3,500 employees responsible for multiple highly-regulated global functions, including regulatory, information technology, internal control and quality, and all 15 of the company\u2019s global manufacturing sites. In addition to his operational duties, Mr. Harbin also held two board-level positions in joint ventures in Japan and China.<\/p>\n

Earlier in his career, Mr. Harbin held multiple leadership roles within Eli Lilly and Company globally, where his responsibilities spanned a variety of business and operations functions, including finance, manufacturing, sales, human resources and people development.<\/p>\n

\n About Oncorus<\/strong>\n <\/p>\n

At Oncorus, we are focused on driving innovation to deliver next-generation viral immunotherapies to transform outcomes for cancer patients. We are advancing a portfolio of intratumorally and intravenously administered viral immunotherapies for multiple indications with significant unmet needs based on our oncolytic Herpes Simplex Virus (oHSV) Platform and Synthetic Virus Platform. Designed to deliver next-generation viral immunotherapy impact, our oHSV Platform improves upon key characteristics of this therapeutic class to enhance potency without sacrificing safety, including greater capacity to encode transgenes to drive systemic immunostimulatory activity, retention of full replication competency to enable high tumor-killing potency, and orthogonal safety strategies to restrict viral activity in tumor cells. Our lead oHSV program, ONCR-177, is designed to be directly administered into a tumor, resulting in high local concentrations of the therapeutic agent, as well as low systemic exposure to the therapy, which we believe could potentially limit systemic toxicities. Please visit us at www.oncorus.com<\/a>\u00a0to learn more.<\/p>\n

\n Cautionary Note Regarding <\/strong>
\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding: expectations with respect to Oncorus\u2019 ability to advance its clinical and pre-clinical pipelines, including statements regarding the clinical development of ONCR-177, expectations regarding upcoming milestones for its other potential product candidates, as well as the therapeutic potential and clinical benefits of Oncorus\u2019 product candidates; Oncorus\u2019 expectations with respect to its continued growth, including its ability to expand its infrastructure and organization and its ability to scale-up its platforms and buildout its manufacturing capabilities; the ability of the leadership team to execute Oncorus\u2019 strategy and support its future growth; and statements regarding the accomplishments, experience and capabilities of individual members of Oncorus\u2019 leadership team and the ability of such qualities to drive Oncorus\u2019 success. The words “may,” \u201cmight,\u201d “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” \u201cexpect,\u201d “estimate,” \u201cseek,\u201d “predict,” \u201cfuture,\u201d “project,” “potential,” “continue,” “target” and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of COVID-19 on Oncorus\u2019 operations and the timing and anticipated results of its ongoing and planned clinical trials; the development of its manufacturing capabilities and progression of its product candidates into the operational scale-up phase; the risk that the results of a clinical trial may not be predictive of future results in connection with future clinical trials; Oncorus\u2019s ability to successfully demonstrate the safety and efficacy of ONCR-177 and obtain regulatory approval; and Oncorus\u2019 ability to obtain, maintain and protect its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Oncorus\u2019 Quarterly Report on Form 10-Q for the quarter ended\u00a0September 30, 2020, which was filed with the\u00a0Securities and Exchange Commission on\u00a0November 12, 2020, as well as discussions of potential risks, uncertainties, and other important factors in the other filings that\u00a0Oncorus\u00a0makes with the\u00a0Securities and Exchange Commission\u00a0from time to time. These documents are available under the \u201cSEC filings\u201d page of the Investors section of Oncorus\u2019s website at\u00a0http:\/\/investors.oncorus.com<\/a>.<\/p>\n

Any forward-looking statements represent Oncorus\u2019 views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date.\u00a0Oncorus\u00a0explicitly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.<\/p>\n\n\n\n\n\n\n
\n Investor Contact:<\/strong>\u00a0\u00a0<\/td>\n\n Media Contact:<\/strong>\n <\/td>\n<\/tr>\n
Alan Lada<\/td>\nLiz Melone<\/td>\n<\/tr>\n
Solebury Trout<\/td>\n\n liz.melone@oncorus.com<\/a>\u00a0<\/td>\n<\/tr>\n
617-221-8006<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n alada@solebury<\/a>
\n trout.com<\/a>\n <\/td>\n		\u00a0<\/td>\n<\/tr>\n<\/table>\n

A photo accompanying this announcement is available at https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/1a8a7d16-f4b6-4a61-ae9f-50b332d79f23<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

— Former Moderna executive and industry veteran brings diverse operational expertise as Oncorus\u00a0plans buildout of its manufacturing capabilities to support its viral immunotherapy pipeline — CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) — Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation viral immunotherapies to transform outcomes for cancer patients, today announced the appointment of Steve Harbin as Chief Operating Officer and Chief of Staff. \u201cI am thrilled to welcome Steve to the Oncorus team. He is uniquely qualified to help steer the strategic growth of our company at this pivotal timepoint,\u201d said Theodore (Ted) Ashburn, M.D. Ph.D., President and CEO of Oncorus. \u201cWe continue to advance the Phase 1 study of our lead viral immunotherapy candidate, ONCR-177, … <\/p>\n

Continue reading “Oncorus Appoints Steve Harbin as Chief Operating Officer and Chief of Staff”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-394181","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nOncorus Appoints Steve Harbin as Chief Operating Officer and Chief of Staff - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncorus Appoints Steve Harbin as Chief Operating Officer and Chief of Staff - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"— Former Moderna executive and industry veteran brings diverse operational expertise as Oncorus\u00a0plans buildout of its manufacturing capabilities to support its viral immunotherapy pipeline — CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) — Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation viral immunotherapies to transform outcomes for cancer patients, today announced the appointment of Steve Harbin as Chief Operating Officer and Chief of Staff. \u201cI am thrilled to welcome Steve to the Oncorus team. He is uniquely qualified to help steer the strategic growth of our company at this pivotal timepoint,\u201d said Theodore (Ted) Ashburn, M.D. Ph.D., President and CEO of Oncorus. \u201cWe continue to advance the Phase 1 study of our lead viral immunotherapy candidate, ONCR-177, … Continue reading "Oncorus Appoints Steve Harbin as Chief Operating Officer and Chief of Staff"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-07T13:03:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Nzc3MiMzODU4Nzk3IzIyMDE0NDQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oncorus Appoints Steve Harbin as Chief Operating Officer and Chief of Staff\",\"datePublished\":\"2020-12-07T13:03:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\\\/\"},\"wordCount\":1229,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5Nzc3MiMzODU4Nzk3IzIyMDE0NDQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\\\/\",\"name\":\"Oncorus Appoints Steve Harbin as Chief Operating Officer and Chief of Staff - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5Nzc3MiMzODU4Nzk3IzIyMDE0NDQ=\",\"datePublished\":\"2020-12-07T13:03:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5Nzc3MiMzODU4Nzk3IzIyMDE0NDQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5Nzc3MiMzODU4Nzk3IzIyMDE0NDQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncorus Appoints Steve Harbin as Chief Operating Officer and Chief of Staff\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncorus Appoints Steve Harbin as Chief Operating Officer and Chief of Staff - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\/","og_locale":"en_US","og_type":"article","og_title":"Oncorus Appoints Steve Harbin as Chief Operating Officer and Chief of Staff - Market Newsdesk","og_description":"— Former Moderna executive and industry veteran brings diverse operational expertise as Oncorus\u00a0plans buildout of its manufacturing capabilities to support its viral immunotherapy pipeline — CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) — Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation viral immunotherapies to transform outcomes for cancer patients, today announced the appointment of Steve Harbin as Chief Operating Officer and Chief of Staff. \u201cI am thrilled to welcome Steve to the Oncorus team. He is uniquely qualified to help steer the strategic growth of our company at this pivotal timepoint,\u201d said Theodore (Ted) Ashburn, M.D. Ph.D., President and CEO of Oncorus. \u201cWe continue to advance the Phase 1 study of our lead viral immunotherapy candidate, ONCR-177, … Continue reading \"Oncorus Appoints Steve Harbin as Chief Operating Officer and Chief of Staff\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-07T13:03:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Nzc3MiMzODU4Nzk3IzIyMDE0NDQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oncorus Appoints Steve Harbin as Chief Operating Officer and Chief of Staff","datePublished":"2020-12-07T13:03:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\/"},"wordCount":1229,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Nzc3MiMzODU4Nzk3IzIyMDE0NDQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\/","name":"Oncorus Appoints Steve Harbin as Chief Operating Officer and Chief of Staff - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Nzc3MiMzODU4Nzk3IzIyMDE0NDQ=","datePublished":"2020-12-07T13:03:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Nzc3MiMzODU4Nzk3IzIyMDE0NDQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Nzc3MiMzODU4Nzk3IzIyMDE0NDQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-appoints-steve-harbin-as-chief-operating-officer-and-chief-of-staff\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oncorus Appoints Steve Harbin as Chief Operating Officer and Chief of Staff"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/394181","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=394181"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/394181\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=394181"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=394181"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=394181"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}